AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1903598 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone infusion (45 ng.kg‐1.min‐1)
Number of subjects: 7
Study 7017100 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (0.05 mg/kg, intravenously administered)
Number of subjects: 0
Study 7017100 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31640997 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM+real tDCS
Number of subjects: 66
Study 31640997 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM+sham tDCS
Number of subjects: 66
Study 31640997 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 66
Study 27875017 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing and semi-liquid diet
Number of subjects: 234
Study 27875017 — intervention group
Group type: COMPARATOR
Intervention: Semi-liquid only diet
Number of subjects: 234
Study 27875017 — intervention group
Group type: COMPARATOR
Intervention: Liquid diet
Number of subjects: 234
Study 26443659 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 minutes of tailored brief advice delivered by dental practitioners during the patient's appointment
Number of subjects: 12
Study 26443659 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study 23373664 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial directly observed antiretroviral therapy (DOT‐ART)
Number of subjects: 172
Study 23373664 — intervention group
Group type: COMPARATOR
Intervention: Self‐administered ART (Self‐ART)
Number of subjects: 172
Study 23373664 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DOT‐ART and Self‐ART
Number of subjects: 172
Study 21447934 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive positive pressure ventilation (NPPV) by mask
Number of subjects: 53
Study 21447934 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV) by helmet
Number of subjects: 53
Study 20031735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine (2 x 120 microg in 20 mL NaCl)
Number of subjects: 448
Study 20031735 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 x 20 mL NaCl)
Number of subjects: 448
Study 20031735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine
Number of subjects: 448
Study 20031735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study 17352768 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 (7.5 MIU twice a day, for 5 days every 8 weeks)
Number of subjects: 1673
Study 15028250 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐UBI
Number of subjects: 6
Study 12365878 — intervention group
Group type: EXPERIMENTAL
Intervention: ethyl-eicosapentaenoate 1 g/d
Number of subjects: 70
Study 12365878 — intervention group
Group type: EXPERIMENTAL
Intervention: ethyl-eicosapentaenoate 2 g/d
Number of subjects: 70
Study 12365878 — intervention group
Group type: EXPERIMENTAL
Intervention: ethyl-eicosapentaenoate 4 g/d
Number of subjects: 70
Study 12365878 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 70
Study 9521435 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene and vitamin A supplementation (30 mg of beta-carotene and 25,000 IU of retinyl palmitate)
Number of subjects: 21
Study 9521435 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene and vitamin A supplementation
Number of subjects: 21
Study 7855556 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem (Imi)
Number of subjects: 91
Study 7855556 — intervention group
Group type: COMPARATOR
Intervention: Combination of tobramycin and cefuroxime (T/C)
Number of subjects: 91
Study 7855556 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin and aztreonam (V/A)
Number of subjects: 91
Study 2535678 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine
Number of subjects: 12
Study 2535678 — intervention group
Group type: EXPERIMENTAL
Intervention: usual anti-hypertensive therapy
Number of subjects: 12
Study 2535678 — intervention group
Group type: COMPARATOR
Intervention: control population
Number of subjects: 12
Study 2535678 — intervention group
Group type: COMPARATOR
Intervention: untreated hypertensive patients
Number of subjects: 12
Study 1096127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol
Number of subjects: 20
Study 1096127 — intervention group
Group type: COMPARATOR
Intervention: Intravenous aminophylline
Number of subjects: 20
Study 31917100 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg/day of ferrous sulfate
Number of subjects: 20
Study 31917100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31682619 — intervention group
Group type: EXPERIMENTAL
Intervention: Using mobile phone
Number of subjects: 125
Study 31682619 — intervention group
Group type: COMPARATOR
Intervention: Sitting alone with no phone
Number of subjects: 125
Study 31682619 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisting the phone
Number of subjects: 125
Study 31682619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with device but resisting use
Number of subjects: 125
Study 28529147 — intervention group
Group type: EXPERIMENTAL
Intervention: norUDCA 500mg/d
Number of subjects: 161
Study 28529147 — intervention group
Group type: EXPERIMENTAL
Intervention: norUDCA 1000mg/d
Number of subjects: 161
Study 28529147 — intervention group
Group type: EXPERIMENTAL
Intervention: norUDCA 1500mg/d
Number of subjects: 161
Study 28529147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 25592163 — intervention group
Group type: EXPERIMENTAL
Intervention: LOCI intervention (6-month duration)
Number of subjects: 100
Study 25592163 — intervention group
Group type: COMPARATOR
Intervention: Two-session leadership webinar control
Number of subjects: 100
Study 25592163 — intervention group
Group type: EXPERIMENTAL
Intervention: LOCI intervention
Number of subjects: 100
Study 23760736 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Sleep Deprivation (PSD)
Number of subjects: 10
Study 23760736 — intervention group
Group type: COMPARATOR
Intervention: Normal Sleep (Norm)
Number of subjects: 10
Study 21711174 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy (2 mg/kg body weight aglycone equivalent isoflavones)
Number of subjects: 30
Study 21711174 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of seaweed (5 g/day) and soy
Number of subjects: 30
Study 21711174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18064563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (daily oral for 6 months)
Number of subjects: 0
Study 18064563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16271911 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop and decision tree
Number of subjects: 249
Study 16271911 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop
Number of subjects: 249
Study 16271911 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree
Number of subjects: 249
Study 16271911 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 249
Study 12665914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine + Thymopentin (Group A)
Number of subjects: 98
Study 12665914 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (Group B)
Number of subjects: 98
Study 12665914 — intervention group
Group type: COMPARATOR
Intervention: Thymopentin (Group C)
Number of subjects: 98
Study 9655431 — intervention group
Group type: COMPARATOR
Intervention: Intact hair follicles (control group A; n = 100)
Number of subjects: 300
Study 9655431 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-half hair follicles (experimental group B; n = 200)
Number of subjects: 300
Study 9655431 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-half hair follicles (experimental group B; n = 200)
Number of subjects: 300
Study 8600607 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg twice daily
Number of subjects: 83
Study 8600607 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg daily
Number of subjects: 83
Study 2510562 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg)
Number of subjects: 20
Study 2510562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1117287 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 0
Study 1117287 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 0
Study 1117287 — intervention group
Group type: COMPARATOR
Intervention: Trifluoperazine
Number of subjects: 0
Study 1117287 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 0
Study 1117287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31726093 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgery without arthrodesis
Number of subjects: 50
Study 29127472 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) group
Number of subjects: 600
Study 29127472 — intervention group
Group type: COMPARATOR
Intervention: No atrial fibrillation (non-AF) group
Number of subjects: 600
Study 26009003 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity games intervention (twice-weekly, 40 min sessions for 6 weeks)
Number of subjects: 55
Study 26009003 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity games intervention (for obese participants)
Number of subjects: 55
Study 26009003 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study 25591636 — intervention group
Group type: EXPERIMENTAL
Intervention: XR‐NTX (380 mg)
Number of subjects: 114
Study 25591636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 22814409 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthrax Vaccine Adsorbed (AVA)
Number of subjects: 1562
Study 22814409 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 1562
Study 22814409 — intervention group
Group type: COMPARATOR
Intervention: Reduced AVA schedule with saline placebo
Number of subjects: 1562
Study 20817409 — intervention group
Group type: EXPERIMENTAL
Intervention: BLING intervention
Number of subjects: 1846
Study 18680075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (0.1 mg bolus, then 35 microg/kg/min for 6 hours, maximum dose 9 mg)
Number of subjects: 208
Study 18680075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 18680075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 208
Study 15647969 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU intranasal salmon calcitonin (Miacalcic nasal 200) daily, 1 month on-1 month off, 0.25 mug 1alpha(OH)D3, and 500 mg elemental calcium continuously
Number of subjects: 102
Study 15647969 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mug 1alpha(OH)D3 and 500 mg elemental calcium
Number of subjects: 102
Study 12034414 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor antagonists
Number of subjects: 12110
Study 12034414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12110
Study 12034414 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (reference drug)
Number of subjects: 12110
Study 9529169 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative abdominal decompression
Number of subjects: 11
Study 8017601 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 300 micrograms
Number of subjects: 34
Study 8017601 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam 10 mg
Number of subjects: 34
Study 2513967 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia carers' programme
Number of subjects: 96
Study 2513967 — intervention group
Group type: COMPARATOR
Intervention: Memory retraining programme
Number of subjects: 96
Study 2513967 — intervention group
Group type: COMPARATOR
Intervention: Wait list group
Number of subjects: 96
Study 9752388 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic mixture containing 10 mg of methylphenidate, 2.5 mg of methandrostenolone, and a mixture of B vitamins
Number of subjects: 32
Study 9752388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 28857996 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturation plus Surgicel application (Group 1)
Number of subjects: 760
Study 28857996 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 2)
Number of subjects: 760
Study 25775686 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-accelerated thrombolysis (UST)
Number of subjects: 60
Study 25775686 — intervention group
Group type: COMPARATOR
Intervention: Standard thrombolysis (ST)
Number of subjects: 60
Study 24088419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity (three 50-minute sessions per week over 10 weeks)
Number of subjects: 0
Study 24088419 — intervention group
Group type: COMPARATOR
Intervention: Health Guidance (90-minute individualised dialogue)
Number of subjects: 0
Study 24088419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity
Number of subjects: 0
Study 24088419 — intervention group
Group type: COMPARATOR
Intervention: Health Guidance
Number of subjects: 0
Study 21418585 — intervention group
Group type: EXPERIMENTAL
Intervention: KRTE only (KO)
Number of subjects: 44
Study 21418585 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture only (AO)
Number of subjects: 44
Study 21418585 — intervention group
Group type: EXPERIMENTAL
Intervention: KRTE and acupuncture combined (KA)
Number of subjects: 44
Study 21418585 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (WL)
Number of subjects: 44
Study 21418585 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (KO, AO, KA, WL)
Number of subjects: 44
Study 18955563 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide-dexamethasone (TD)
Number of subjects: 289
Study 18955563 — intervention group
Group type: COMPARATOR
Intervention: Melphalan-prednisolone (MP)
Number of subjects: 289
Study 17996140 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous thrombectomy
Number of subjects: 68
Study 17996140 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 68
Study 15475141 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.05 mg/kg/day
Number of subjects: 76
Study 15475141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 11501649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel sulfate patch test
Number of subjects: 589
Study 11501649 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium dichromate patch test
Number of subjects: 589
Study 9603111 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 40
Study 9603111 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study 7921095 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime for 10 days
Number of subjects: 484
Study 7921095 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime for 5 days
Number of subjects: 484
Study 7921095 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V for 10 days
Number of subjects: 484
Study 30110336 — intervention group
Group type: EXPERIMENTAL
Intervention: DIABSCORE ≥ 90
Number of subjects: 225
Study 30110336 — intervention group
Group type: EXPERIMENTAL
Intervention: DIABSCORE ≥ 80
Number of subjects: 225
Study 30110336 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curves for T2D
Number of subjects: 225
Study 30110336 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curves for prediabetes
Number of subjects: 225
Study 29947487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (40 ml of 0.25% solution)
Number of subjects: 62
Study 29947487 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 62
Study 23884391 — intervention group
Group type: EXPERIMENTAL
Intervention: LogMAR visual acuity
Number of subjects: 83
Study 23884391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelli Robson contrast sensitivity
Number of subjects: 83
Study 23884391 — intervention group
Group type: EXPERIMENTAL
Intervention: LogMAR reading acuity
Number of subjects: 83
Study 23884391 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading speed
Number of subjects: 83
Study 23884391 — intervention group
Group type: EXPERIMENTAL
Intervention: LogMAR critical print size
Number of subjects: 83
Study 22285109 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric systemic anticoagulation (ESA)
Number of subjects: 7932
Study 22285109 — intervention group
Group type: COMPARATOR
Intervention: No empiric systemic anticoagulation (ESA)
Number of subjects: 7932
Study 20450425 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with 400 mg ropivacaine, 30 mg ketorolac, and 0.5 mg epinephrine during operation and 200 mg ropivacaine, 30 mg ketorolac, and 0.1 mg epinephrine 21 h postoperatively
Number of subjects: 48
Study 20450425 — intervention group
Group type: COMPARATOR
Intervention: Control group with no injections during operation and saline injection 21 h postoperatively
Number of subjects: 48
Study 20450425 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 48
Study 18481390 — intervention group
Group type: EXPERIMENTAL
Intervention: Oregovomab immunotherapy
Number of subjects: 145
Study 18481390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 16527015 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisseel (2 cc)
Number of subjects: 60
Study 16527015 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 12660408 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrH2O) supplementation (0.5 g x kg(‐1) FFM, one fourth dosage 4 times daily for 5 days)
Number of subjects: 22
Study 12660408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10962639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐sacral neurectomy
Number of subjects: 0
Study 10962639 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterosacral ligament resection
Number of subjects: 0
Study 10962639 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 0
Study 10962639 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesiolysis
Number of subjects: 0
Study 9014620 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 50 micrograms kg-1
Number of subjects: 90
Study 9014620 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 20 micrograms kg-1
Number of subjects: 90
Study 9014620 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 10 micrograms kg-1
Number of subjects: 90
Study 9014620 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (various doses)
Number of subjects: 90
Study 9014620 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (doses > 20 micrograms kg-1)
Number of subjects: 90
Study 9014620 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 50 micrograms kg-1 or more
Number of subjects: 90
Study 9014620 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg kg-1
Number of subjects: 90
Study 1312888 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 10
Study 1312888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3926591 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms b.i.d.
Number of subjects: 10
Study 3926591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 600 mg b.i.d.
Number of subjects: 10
Study 3926591 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms h.s.
Number of subjects: 10
Study 3926591 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms h.s.
Number of subjects: 10
Study 3926591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31032782 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory rehabilitation (10 weekly sessions of a manualised memory rehabilitation programme)
Number of subjects: 328
Study 31032782 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory rehabilitation
Number of subjects: 328
Study 31032782 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 328
Study 29418016 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.67 mg/m2/day)
Number of subjects: 27
Study 29418016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 29418016 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 27
Study 29418016 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment with Sex Steroid Replacement Therapy (SSRT)
Number of subjects: 27
Study 26817525 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tramadol 50 mg
Number of subjects: 140
Study 26817525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 25455115 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions-based intervention
Number of subjects: 470
Study 25455115 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (generic health information on diet and exercise)
Number of subjects: 470
Study 22329446 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 74
Study 22329446 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (physical therapy, topical dimethyl sulfoxide, analgesics, transcutaneous stimulation, sympathetic blockade)
Number of subjects: 74
Study 20192532 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifier-noun combinations with varying semantic categories
Number of subjects: 0
Study 20192532 — intervention group
Group type: EXPERIMENTAL
Intervention: Head noun with compatible semantic category of the modifier
Number of subjects: 0
Study 17602007 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment
Number of subjects: 38
Study 15744348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 6-mercaptopurine (1 g/m(2))
Number of subjects: 877